The aim of this study was to determine whether the driving-related cognitive performance differs among adults with schizophrenia taking different types of antipsychotics. Neurocognitive performance was assessed using the Cognitive Perceptual Assessment for Driving (CPAD), a computerized battery of tests of visual perception, attention, working memory, reaction time, and inhibitory control for driving ability. One hundred and two adults with schizophrenia who were on antipsychotic monotherapy participated in the study. Of these, 15 were on haloperidol, 28 on risperidone, 14 on olanzapine, 28 on aripiprazole, and 17 on paliperidone. Sixty-four (63%) of the 102 subjects were regarded as competent to drive. Of the subjects taking haloperidol, 33% passed the CPAD, while the passing rates of subjects taking risperidone, olanzapine, aripiprazole, and paliperidone were 57%, 57%, 75%, and 82%, respectively, with a significant difference between the haloperidol and aripiprazole groups (p = 0.005) and between the haloperidol and paliperidone groups (p = 0.001). Additionally, scores on CPAD depth perception (number of correct responses), divided attention, digit span test, and trail-making test B subtests were significantly better for the aripiprazole and paliperidone groups than for the haloperidol and risperidone groups. In this cross-sectional design study, adults with schizophrenia treated with aripiprazole or paliperidone antipsychotic monotherapy demonstrated superior driving-related cognitive performance than those treated with haloperidol or risperidone antipsychotic monotherapy.

这项研究的目的是确定服用不同类型抗精神病药的精神分裂症成年人之间与驾驶相关的认知表现是否有所不同。使用驾驶认知认知评估（CPAD）来评估神经认知表现，CPAD是计算机化的一系列视觉感知，注意力，工作记忆，反应时间以及对驾驶能力的抑制性控制测试。接受抗精神病药物单一疗法治疗的120位精神分裂症成人参加了该研究。其中，氟哌啶醇有15种，利培酮有28种，奥氮平有14种，阿立哌唑有28种，帕潘立酮有17种。102名受试者中有64名（63％）被认为具有驾驶能力。在服用氟哌啶醇的受试者中，有33％通过了CPAD，而服用利培酮，奥氮平，阿立哌唑，和氟哌啶酮分别为57％，57％，75％和82％，氟哌啶醇和阿立哌唑组之间的差异显着（p = 0.005），氟哌啶醇和帕潘立酮的组之间差异显着（p = 0.001）。此外，对于阿立哌唑和帕潘立酮组，CPAD深度知觉（正确答案的数量），注意力分散，手指跨度测试和追踪测试B子测试的得分显着优于氟哌啶醇和利培酮组。在这项横断面设计研究中，使用阿立哌唑或帕潘立酮抗精神病药物单药治疗的精神分裂症成年人比与氟哌啶醇或利培酮抗精神病药物单药治疗的成年人表现出更好的驾驶相关认知能力。氟哌啶醇和阿立哌唑组之间存在显着差异（p = 0.005），氟哌啶醇和帕潘立酮组之间存在显着差异（p = 0.001）。此外，对于阿立哌唑和帕潘立酮组，CPAD深度知觉（正确答案的数量），注意力分散，手指跨度测试和追踪测试B子测试的得分显着优于氟哌啶醇和利培酮组。在这项横断面设计研究中，使用阿立哌唑或帕潘立酮抗精神病药物单药治疗的精神分裂症成年人比与氟哌啶醇或利培酮抗精神病药物单药治疗的成年人表现出更好的驾驶相关认知能力。氟哌啶醇和阿立哌唑组之间存在显着差异（p = 0.005），氟哌啶醇和帕潘立酮组之间存在显着差异（p = 0.001）。此外，对于阿立哌唑和帕潘立酮组，CPAD深度知觉（正确答案的数量），注意力分散，手指跨度测试和追踪测试B子测试的得分显着优于氟哌啶醇和利培酮组。在这项横断面设计研究中，使用阿立哌唑或帕潘立酮抗精神病药物单一疗法治疗的精神分裂症成年人比与氟哌啶醇或利培酮抗精神病药物单一疗法治疗的成年人具有更好的驾驶相关认知能力。阿立哌唑和帕潘立酮组的CPAD深度知觉（正确反应次数），注意力分散度，手指跨度测试和追踪测试B子项得分显着优于氟哌啶醇和利培酮组。在这项横断面设计研究中，使用阿立哌唑或帕潘立酮抗精神病药物单一疗法治疗的精神分裂症成年人比与氟哌啶醇或利培酮抗精神病药物单一疗法治疗的成年人具有更好的驾驶相关认知能力。阿立哌唑和帕潘立酮组的CPAD深度知觉（正确反应次数），注意力分散度，手指跨度测试和追踪测试B子项得分明显优于氟哌啶醇和利培酮组。在这项横断面设计研究中，使用阿立哌唑或帕潘立酮抗精神病药物单一疗法治疗的精神分裂症成年人比与氟哌啶醇或利培酮抗精神病药物单一疗法治疗的成年人具有更好的驾驶相关认知能力。